Foghorn Therapeutics (FHTX) vs Seer (SEER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Seer (SEER) has outperformed Foghorn Therapeutics (FHTX) over the past year, losing 0.5% versus a loss of 52.7%. Over five years, FHTX leads with a -83.1% price change compared with -93.3% for SEER. Foghorn Therapeutics is the larger company by market cap ($124.1 million vs $122.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | SEER |
|---|---|---|
| Share price | $2.09 | $2.21 |
| Market cap | $124.12M | $122.37M |
| 1-day change | +6.09% | +0.91% |
| YTD return | -61.30% | +20.77% |
| 1-year return | -52.71% | -0.45% |
| 5-year return | -83.12% | -93.30% |
| EPS (TTM) | $-0.98 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.61 | $2.41 |
| 52-week low | $1.79 | $1.55 |
| Distance from 52-week high | -72.54% | -8.30% |
| Analyst consensus | buy | none |
| Avg. price target upside | +187.08% | +81.00% |
| Average volume | 611.95K | 498.15K |
| Shares outstanding | 59.39M | 55.37M |
| Employees | 106 | 124 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEER has outperformed FHTX by 52.3 percentage points over the past year.
- The two companies sit in different sectors: Foghorn Therapeutics in Health Care and Seer in Industrials.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Seer
SEER stock →Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Industrials · Biotechnology: Laboratory Analytical Instruments · 124 employees
FHTX vs SEER FAQ
Which is bigger, Foghorn Therapeutics or Seer?
Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $124.12M compared with $122.37M for Seer (SEER).
Which stock has performed better over the past year, FHTX or SEER?
SEER returned -0.45% over the past 12 months, compared with -52.71% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and Seer in the same industry?
No. Foghorn Therapeutics is in the Health Care sector, while Seer is in Industrials.